TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7877292

Group type: EXPERIMENTAL
Intervention: Proband adults with moderate phonological disorder
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control adults with average articulation skills
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 3064775

Group type: EXPERIMENTAL
Intervention: Radiotherapy + tamoxifen (TAM), 30 mg daily for 1 year
Number of subjects: 3063

Group type: EXPERIMENTAL
Intervention: TAM alone
Number of subjects: 3063

Group type: EXPERIMENTAL
Intervention: TAM + CMF (CMF i.v. day 1 every 4 weeks x 9)
Number of subjects: 3063

Group type: COMPARATOR
Intervention: Postoperative radiotherapy
Number of subjects: 3063
Study: 31451364

Group type: EXPERIMENTAL
Intervention: Tablet-based PAINUCope intervention focused on barriers to pain management, pain, and analgesic adherence
Number of subjects: 228

Group type: COMPARATOR
Intervention: Usual care (selection of games)
Number of subjects: 228
Study: 31033909

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (L. reuteri)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26123256

Group type: EXPERIMENTAL
Intervention: Lisinopril 2.5 mg once daily for 26 weeks
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 23991896

Group type: EXPERIMENTAL
Intervention: subcutaneous immunotherapy with mixed depigmented‐polymerized birch and grass pollen extract
Number of subjects: 285

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 285
Study: 21692844

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 624
Study: 19267255

Group type: EXPERIMENTAL
Intervention: Aripiprazole treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 0
Study: 17040583

Group type: EXPERIMENTAL
Intervention: Functional neck dissection (FND)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Radical neck dissection (RND)
Number of subjects: 21
Study: 15493172

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy performed for six cytology-positive patients (group I)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: No adjuvant therapy for six cytology-positive patients (group II)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No adjuvant therapy for twelve cytology-negative patients (control group)
Number of subjects: 24
Study: 11550726

Group type: EXPERIMENTAL
Intervention: Increased therapist self-disclosure during treatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: No therapist self-disclosure during treatment
Number of subjects: 2
Study: 9590464

Group type: EXPERIMENTAL
Intervention: Baclofen 20 mg once daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: COMPARATOR
Intervention: Baclofen 10 mg once daily
Number of subjects: 41
Study: 7930702

Group type: EXPERIMENTAL
Intervention: Visceral leishmaniasis (VL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cutaneous leishmaniasis (CL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both VL and CL
Number of subjects: 0
Study: 2896128

Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg
Number of subjects: 91

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 91
Study: 30601453

Group type: EXPERIMENTAL
Intervention: Most Bothersome Symptom Approach (MBSA)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Atrophy Symptoms Questionnaire (ASQ)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Correlation between MBSA and ASQ
Number of subjects: 31
Study: 27281800

Group type: EXPERIMENTAL
Intervention: 1.5 g SR-l-arginine 3 times/d (4.5 g/d)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 25716649

Group type: EXPERIMENTAL
Intervention: L50/H12.5/A5
Number of subjects: 327

Group type: COMPARATOR
Intervention: L50+A5
Number of subjects: 327
Study: 24260825

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (100 mg and 200 mg every 12 hours for 3 days)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Paromomycin (25 mg/kg/day for 2 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 90
Study: 20374563

Group type: EXPERIMENTAL
Intervention: Continuous antiretroviral therapy (C-ART)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Interrupted antiretroviral therapy (2-months-off/4-months-on cycles [2/4-ART])
Number of subjects: 192
Study: 17977618

Group type: EXPERIMENTAL
Intervention: Nibble-size snack in control condition
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Bar-size snack in control condition
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Attention to consumption (chewing well)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control condition (no instruction to chew well)
Number of subjects: 59
Study: 16873974

Group type: EXPERIMENTAL
Intervention: ipsilateral rTMS (IS group)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: contralateral rTMS (CS group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: sham rTMS (SS group)
Number of subjects: 27
Study: 12891163

Group type: EXPERIMENTAL
Intervention: Psychological interventions (specific details not provided)
Number of subjects: 0
Study: 10877493

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (5,000 IU retinyl palmitate and 30 mg beta-carotene daily, plus 200,000 IU retinyl palmitate at delivery)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 8940670

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral ganciclovir
Number of subjects: 0
Study: 1549654

Group type: COMPARATOR
Intervention: High-osmolality contrast material
Number of subjects: 2113

Group type: EXPERIMENTAL
Intervention: Low-osmolality contrast material
Number of subjects: 2113
Study: 3933067

Group type: EXPERIMENTAL
Intervention: Propranolol (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mepindolol (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salbutamol (20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30865078

Group type: EXPERIMENTAL
Intervention: Higher 30-day seizure frequency
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lower quality of life
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Comorbid bipolar disorder
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Comorbid panic disorder
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Comorbid obsessive-compulsive disorder
Number of subjects: 120
Study: 30055046

Group type: EXPERIMENTAL
Intervention: Samidorphan 10 mg/d
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Samidorphan 2.5 mg/d
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Samidorphan 1 mg/d
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study: 27091619

Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy within 72 hours
Number of subjects: 64

Group type: COMPARATOR
Intervention: Delayed cholecystectomy after 68 weeks
Number of subjects: 64
Study: 25145456

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab treatment
Number of subjects: 84
Study: 22702506

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 (6 × 10(9) cfu/day)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Bifidobacterium animalis subsp lactis HN019 (9 × 10(9) cfu/day)
Number of subjects: 425
Study: 20602089

Group type: EXPERIMENTAL
Intervention: D: ‐amphetamine (0.3 mg/kg, p.o.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18845497

Group type: EXPERIMENTAL
Intervention: 50 Gy whole-breast irradiation (WBI)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: 50 Gy whole-breast irradiation (WBI) plus 16 Gy tumour bed boost
Number of subjects: 278

Group type: COMPARATOR
Intervention: Reoperation (reexcision plus radiotherapy or mastectomy alone)
Number of subjects: 278
Study: 16093996

Group type: EXPERIMENTAL
Intervention: 50 mg oral rofecoxib
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac (3 doses, 8-hourly)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 14642554

Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid (VIA) screening by nurses
Number of subjects: 78292

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 78292

Group type: EXPERIMENTAL
Intervention: Treatment received after diagnosis
Number of subjects: 78292
Study: 11016665

Group type: EXPERIMENTAL
Intervention: Barrier creams (3 representative commercial barrier creams)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control skin (no barrier cream used)
Number of subjects: 6
Study: 8989723

Group type: EXPERIMENTAL
Intervention: Melatonin (20 mg/day orally in the evening)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study: 1620139

Group type: EXPERIMENTAL
Intervention: Physostigmine (0.02 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atropine (0.04 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6151914

Group type: EXPERIMENTAL
Intervention: Oxatomide 30 mg b.i.d. for 2 months
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oxatomide
Number of subjects: 35
Study: 30661474

Group type: EXPERIMENTAL
Intervention: 1000 mg/d sodium diet
Number of subjects: 17

Group type: COMPARATOR
Intervention: 2300 mg/d sodium diet
Number of subjects: 17
Study: 29278529

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 IU
Number of subjects: 44

Group type: COMPARATOR
Intervention: 1 mL sodium chloride 0.9 (placebo)
Number of subjects: 44
Study: 27270263

Group type: EXPERIMENTAL
Intervention: L‐thyroxine replacement therapy
Number of subjects: 378

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 378
Study: 24610399

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) and quitline referral (Group MNQ)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) and quitline referral (Group UNQ)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Quitline referral only (Group UQ)
Number of subjects: 157
Study: 22270321

Group type: EXPERIMENTAL
Intervention: S-warfarin (25 mg single oral dose)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Optimal PK sampling schedule
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Selected PK sampling time points
Number of subjects: 19
Study: 19811890

Group type: EXPERIMENTAL
Intervention: Coordination therapy (CTh)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional voice therapy
Number of subjects: 68
Study: 17918147

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Systemic heparin anticoagulation
Number of subjects: 48
Study: 16239862

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 11543743

Group type: EXPERIMENTAL
Intervention: Galanthamine (cholinergic REM induction test, CRIT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Baseline conditions (alcohol-dependent patients)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patients who remained abstinent (n=11)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control subjects (age- and gender-matched)
Number of subjects: 40
Study: 9603127

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (inhNO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 30
Study: 7995617

Group type: EXPERIMENTAL
Intervention: Continuous plus pulsatile overnight GH administration (50% constant delivery + 3 pulses)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Single daily injection of GH
Number of subjects: 10
Study: 3593904

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (oral doses)
Number of subjects: 15
Study: 29797217

Group type: EXPERIMENTAL
Intervention: Intensive care management
Number of subjects: 1178

Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 1178
Study: 27359223

Group type: EXPERIMENTAL
Intervention: Add-on EVT
Number of subjects: 264

Group type: COMPARATOR
Intervention: IV tPA alone
Number of subjects: 264
Study: 24931747

Group type: EXPERIMENTAL
Intervention: China rubra 7CH plus quinine
Number of subjects: 211

Group type: COMPARATOR
Intervention: Quinine only (Standard group)
Number of subjects: 211
Study: 24113040

Group type: EXPERIMENTAL
Intervention: Telmisartan and amlodipine taken in the morning
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Telmisartan and amlodipine taken at bedtime
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Telmisartan in the morning and amlodipine at bedtime
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Amlodipine in the morning and telmisartan at bedtime
Number of subjects: 108
Study: 21462101

Group type: EXPERIMENTAL
Intervention: Cycle ergometer training 3 times per week, average 25 min at 0.6 watt/kg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group without sports therapy
Number of subjects: 23
Study: 17870051

Group type: EXPERIMENTAL
Intervention: Winter conditions (without air-conditioning)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Summer conditions (without air-conditioning)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Room heating in winter
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Air-conditioning in summer
Number of subjects: 50
Study: 16848200

Group type: EXPERIMENTAL
Intervention: Topical antiglaucoma therapy with pilocarpine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical antiglaucoma therapy with latanoprost and pilocarpine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% and pilocarpine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (only pilocarpine)
Number of subjects: 0
Study: 12482640

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 10682948

Group type: EXPERIMENTAL
Intervention: Vignette of a geriatric, retired patient (n = 100 participants)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Vignette of a younger, employed patient (n = 115 participants)
Number of subjects: 215
Study: 9080750

Group type: EXPERIMENTAL
Intervention: Paired stud retention
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Paired magnetic retention
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Overall treatment success rating
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Healing following Stage I surgery
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Healing following Stage II surgery
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Post-insertion care events
Number of subjects: 25
Study: 8401094

Group type: EXPERIMENTAL
Intervention: Medical abortion with mifepristone 600 mg followed by gemeprost 1 mg vaginal pessary
Number of subjects: 363

Group type: COMPARATOR
Intervention: Vacuum aspiration under general anaesthesia
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Either method (random allocation)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Vacuum aspiration
Number of subjects: 363
Study: 6356325

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trimethoprim and Sulphamethoxazole (TMP-SMX)
Number of subjects: 0
Study: 29945799

Group type: EXPERIMENTAL
Intervention: Hydrus Microstent (HMS)
Number of subjects: 556

Group type: COMPARATOR
Intervention: No Microstent (NMS)
Number of subjects: 556
Study: 29962422

Group type: COMPARATOR
Intervention: Mechanical Tooth Cleaning (MTC)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: MTC + Ultrasonic Debridement using Universal Insert (UDUI)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: MTC + Ultrasonic Debridement using Probe-shaped Insert (UDPI)
Number of subjects: 37
Study: 26562709

Group type: EXPERIMENTAL
Intervention: Milk protein (12 g protein, 7 g essential amino acids)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Soy protein (12 g protein, 7 g essential amino acids)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Rice milk (nonprotein control, 12 g protein, 7 g essential amino acids)
Number of subjects: 26
Study: 24709513

Group type: EXPERIMENTAL
Intervention: CBCT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 40
Study: 21309653

Group type: EXPERIMENTAL
Intervention: Probiotic drop (Lactobacillus reuteri)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo drop
Number of subjects: 19
Study: 19560838

Group type: EXPERIMENTAL
Intervention: 1+1 hydromorphone patient‐driven protocol (1 mg IV hydromorphone followed by a second 1‐mg dose 15 minutes later if requested)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Traditional physician‐driven administration of opioids (any IV opioid at the discretion of the attending physician)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 1+1 hydromorphone patient‐driven protocol
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 1+1 hydromorphone patient‐driven protocol and Traditional physician‐driven administration
Number of subjects: 94
Study: 17955433

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 12343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12343
Study: 16763407

Group type: EXPERIMENTAL
Intervention: naproxen sodium
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: meloxicam
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: rofecoxib
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: paracetamol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: dipyrone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: etodolac
Number of subjects: 120
Study: 15375100

Group type: EXPERIMENTAL
Intervention: Complete intervention arm (systematic strategy with feedback, education, and quality improvement sessions)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Feedback arm (feedback only)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Complete intervention arm (systematic strategy)
Number of subjects: 194
Study: 15321106

Group type: EXPERIMENTAL
Intervention: Warm saline (37 degrees C)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Cold saline (21 degrees C)
Number of subjects: 113
Study: 8794833

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 38
Study: 1825515

Group type: EXPERIMENTAL
Intervention: dichloromethylene diphosphonate (CL2MDP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 38
Study: 6373344

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (50 mg b.d. for the first three months, with possible increase of 50 mg after the third and/or sixth month if PaO2 increase is less than 5 mmHg and well tolerated)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30286303

Group type: EXPERIMENTAL
Intervention: Fortified milk (200 mL daily, enriched with 3 μg of vitamin D3)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Nonfortified milk (200 mL daily, natural abundance of vitamin D3, about 1.5 μg)
Number of subjects: 239
Study: 28783201

Group type: EXPERIMENTAL
Intervention: 6 months DAPT in low DAPT score group
Number of subjects: 3976

Group type: EXPERIMENTAL
Intervention: 12 months DAPT in low DAPT score group
Number of subjects: 3976

Group type: EXPERIMENTAL
Intervention: 6 months DAPT in high DAPT score group
Number of subjects: 3976

Group type: EXPERIMENTAL
Intervention: 12 months DAPT in high DAPT score group
Number of subjects: 3976
Study: 25106026

Group type: EXPERIMENTAL
Intervention: Cardiovascular plus resistance training (CRT)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High‐intensity strength training (HIST)
Number of subjects: 64

Group type: COMPARATOR
Intervention: No exercise (Control)
Number of subjects: 64
Study: 23999280

Group type: EXPERIMENTAL
Intervention: Low-glycemic index dietary intervention for 12 weeks
Number of subjects: 21
Study: 21114545

Group type: EXPERIMENTAL
Intervention: HDUP
Number of subjects: 41

Group type: COMPARATOR
Intervention: MDUP
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: DUP increase
Number of subjects: 41
Study: 17960410

Group type: EXPERIMENTAL
Intervention: Debridement 6 and 12 days postoperatively
Number of subjects: 121

Group type: COMPARATOR
Intervention: Saline irrigation
Number of subjects: 121

Group type: COMPARATOR
Intervention: Packing in middle meatus for 5 days
Number of subjects: 121
Study: 16755554

Group type: EXPERIMENTAL
Intervention: Pramipexole (0.125 to 0.75 mg/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 12580994

Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (active, normolipidaemic)
Number of subjects: 11
Study: 10952698

Group type: EXPERIMENTAL
Intervention: Increased iodine intake (272 microg/l) in preterm formula
Number of subjects: 121

Group type: COMPARATOR
Intervention: Standard iodine intake (68 microg/l) in preterm formula
Number of subjects: 121
Study: 8776813

Group type: EXPERIMENTAL
Intervention: 3-month depot formulation
Number of subjects: 159

Group type: COMPARATOR
Intervention: 1-month depot formulation
Number of subjects: 159
Study: 8529150

Group type: EXPERIMENTAL
Intervention: Titanium miniplates with IMF only during surgery, released thereafter; one titanium mini-plate for angle fractures, two for fractures anterior to the mental foramen.
Number of subjects: 74

Group type: COMPARATOR
Intervention: Open reduction and intermaxillary fixation (IMF) for 5 weeks; stainless steel wire for angle fractures, stainless steel plate for fractures anterior to the mental foramen.
Number of subjects: 74
Study: 6511996

Group type: EXPERIMENTAL
Intervention: Haloperidol (dose mg/kg/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Haloperidol serum concentrations (15 to 40 ng/ml)
Number of subjects: 21
Study: 30768684

Group type: EXPERIMENTAL
Intervention: Oral briefing followed by a 4-min planning discussion
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no planning discussion)
Number of subjects: 44
Study: 28277391

Group type: EXPERIMENTAL
Intervention: Continuous supportive care
Number of subjects: 72

Group type: COMPARATOR
Intervention: Routine hospital care
Number of subjects: 72
Study: 27864246

Group type: EXPERIMENTAL
Intervention: What Were We Thinking (WWWT) psychoeducational intervention
Number of subjects: 359

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 359